• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Akanda Corp. (Amendment)

    2/20/24 6:01:03 PM ET
    $AKAN
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $AKAN alert in real time by email
    SC 13D/A 1 sc13a1.htm SCHEDULE 13D AMENDMENT NO. 1



    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Amendment No. 1 to
    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    AKANDA CORP.
    (Name of Issuer)

     
    Common Shares, no par value
    (Title of Class of Securities)

    00971M205
    (CUSIP Number)

    Katie Field, Chairman & CEO
    Halo Collective Inc.
    65 Queen Street W., Suite 815
    Toronto, Ontario M5H 2M5 Canada

    Copy to:
    Richard Raymer
    Dorsey & Whitney LLP
    161 Bay Street, Suite 4310
    Toronto, Ontario M5J 2S1 Canada
    (416) 367-7370
    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    January 30, 2024
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    CUSIP No. 00971M205
    1
    NAME OF REPORTING PERSONS
    Halo Collective Inc. (the “Reporting Person”)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
    (b) ☐
    3
    SEC USE ONLY
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2 ☐
    Not Applicable
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Ontario, Canada
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON
    WITH:
    7
    SOLE VOTING POWER
    24,992
    8
    SHARED VOTING POWER
    0
    9
    SOLE DISPOSITIVE POWER
    24,992
    10
    SHARED DISPOSITIVE POWER
    0
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    24,992
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) ☐
    NOT APPLICABLE
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
    <5%(1)
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
    CO

    (1)   The percentages used herein are calculated based upon 5,628,295 outstanding shares of the Issuer as of January 29, 2024.


    Item 1.
    Security and Issuer
    (a)
    Title of Class of Securities:
    Common Shares, no par value (the “Common Stock”)
    (b)
    Name of Issuer:
    Akanda Corp. (the “Issuer”)
    (c)
    Address of Issuer’s Principal Executive Offices:
    1a, 1b Learoyd Road
    New Romney, TN28 8XU, United Kingdom
    Item 2.
    Identity and Background
    (a)
    Name of Reporting Person:  Halo Collective Inc.
    (b)
    Principal Business Address:  65 Queen Street West, Suite 815, Toronto, Ontario M5H 2M5 Canada
    (c)
    Occupation, Employment and Other Information:  Cannabis cultivation, extraction, manufacturing and distribution;
    (d)
    Criminal Convictions:  Neither the Reporting Person nor its officers or directors have, in the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors);
    (e)
    Civil Proceedings:  Neither the Reporting Person nor its officers or directors have, in the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding been subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws;
    (f)
    Citizenship:  Ontario, Canada.
    Item 3.
    Source and Amount of Funds or Other Consideration:
    OO - See Item 4
    Item 4.
    Purpose of Transaction
    On January 26, 2024, the Reporting Person entered into a share purchase agreement with 1173727 BC Ltd. for the private resale of 557,200 shares of Common Stock.


    Item 5.
    Interest in Securities of the Issuer
    As of January 30, 2024, the Reporting Person holds the following shares of Common Stock:
    (i) Sole power to vote or to direct the vote:  24,992
    (ii) Shared power to vote or to direct the vote: 0
    (iii) Sole power to dispose or direct the disposition:  24,992
    (iv) Shared power to dispose or direct the disposition: 0
    (v) Aggregate amount of shares beneficially owned:  24,992
    (vi) Percent of class represented in Item (v) above:  <5%
    The percentage represented in Item 5(vi) above was calculated based upon 5,628,295 outstanding shares of the Issuer as of January 29, 2024.

    Item 6.
    Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer
    January 26, 2024 Share Purchase Agreement
    Item 7.
    Material to Be Filed as Exhibits

    January 26, 2024 Share Purchase Agreement
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    Dated: February 16, 2024
    HALO COLLECTIVE INC.

    By:  /s/ Katie Field 
    Katie Field, Chairman & CEO


    EXHIBIT 7.1   Share Purchase Agreement
    This AGREEMENT effective as of January 26, 2024.

    SHARE PURCHASE AGREEMENT

    BETWEEN:

    Halo Collective Inc.
    77 King Street West, Suite 400| Toronto, Ontario
    M5K 0A1

    (the “Vendor”)

    AND:

    1173727 BC LTD.
    10511 Palmberg Road,
    Richmond, BC

    (the “Purchaser”)

    WHEREAS:
    A.
    The Vendor is the beneficial owner of 557,200 common shares in the capital of Akanda Corp. (the “Company”); and

    B.
    The Vendor has agreed to sell and the Purchaser has agreed to purchase 557,200 common shares in the capital of Akanda Corp. (the “Shares”) owned by the Vendor on the terms and conditions hereinafter set forth in this Agreement.

    THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged by each of the parties), the parties covenant and agree as follows:

    1.
    Purchase and Sale

    1.1
    On the basis of the representations and warranties of the parties to this Agreement and subject to the terms and conditions of this Agreement, the Purchaser agrees to purchase from the Vendor, and the Vendor agrees to sell to the Purchaser, the Shares. The purchase price of the Shares is the sum of $0.28693 per Share for an aggregate purchase price of $159,877.40 (the “Purchase Price”).

    1.2
    The closing of the purchase and sale of the Shares (the “Closing”) will take place on or before Jan 30, 2024 or such other date as may be agreed to by the parties hereto (the “Closing Date”). The Closing may take place by exchange of appropriate solicitor’s undertakings, which will involve each party’s solicitors delivering to his or her counterparts all required consideration and documentation, to be held in trust and not released until all required closing deliveries have been made and all conditions to Closing have been satisfied or waived by the party which has the benefit of such conditions.

    1.3
    On the Closing Date, the Purchaser will pay the Vendor the Purchase Price by delivering funds to the Vendor in the amount of the Purchase Price.

    1.4
    On the Closing Date, the Vendor will deliver to the Purchaser, the following documents:

    (a)
    share certificates representing the Shares together with one or more stock transfer powers of attorney, duly endorsed by the Vendor for transfer in form acceptable to the Company for the purposes of effecting the registration of the Shares in the name of the Purchaser; and

    (b)
    all other documents and instruments as the Purchaser may reasonably require.

    2.
    Representations and Warranties

    2.1
    The Vendor represents and warrants to the Purchaser (which representations and warranties shall survive the closing of the transactions contemplated in this Agreement), with the intent that the Purchaser will rely thereon in entering into this Agreement and in concluding the purchase and sale of the Shares as contemplated herein, that:

    (a)
    the Vendor is the beneficial and registered owner of the Shares free and clear of all liens, charges and encumbrances of any kind whatsoever;

    (b)
    other than as has been disclosed to the Purchaser, there are no written instruments, buy-sell agreements, registration rights or agreements, voting agreements or other agreements by and between or among the Vendor or any other person, imposing any restrictions upon the transfer, prohibiting the transfer of or otherwise pertaining to the Shares or the ownership thereof;

    (c)
    the Vendor has the power and capacity and good and sufficient right and authority to enter into this Agreement on the terms and conditions set forth in this Agreement and to transfer the legal and beneficial title and ownership of the Shares to the Purchaser;

    (d)
    no person, firm, corporation or entity of any kind has or will have any agreement or option or any right capable at any time of becoming an agreement to:

    (i)
    purchase or otherwise acquire the Shares; or

    (ii)
    require the Vendor to sell, transfer, assign, pledge, charge, mortgage or in any other way dispose of or encumber any of the Shares other than under this Agreement; and
    (i)




    (e) this Agreement and all other documents required to be executed and delivered by the Vendor have been duly, or will when executed and delivered be duly, executed and delivered by the Vendor, and constitute the legal, valid and binding obligations of the Vendor, enforceable against the Vendor in accordance with their terms, subject to laws of general application relating to bankruptcy, insolvency, the relief of debtors, specific performance, injunctive relief and other equitable remedies.

    2.2
    The Purchaser represents and warrants to the Vendor (which representations and warranties shall survive the closing of the transactions contemplated in this Agreement), with the intent that the Vendor will rely thereon in entering into this Agreement and in concluding the purchase and sale of the Shares as contemplated herein, that it:

    (a)
    the Purchaser has the power and capacity and good and sufficient right and authority to enter into this Agreement on the terms and conditions set forth in this Agreement;

    (b)
    the Purchaser has not taken any action which would impose any obligation or liability to  any  person in  connection  with the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby;

    (c)
    the sale of the Shares to the Purchaser as contemplated in this Agreement complies with or is exempt from the applicable securities legislation of the jurisdiction of residence of the Purchaser;

    (d)
    the Purchaser has adequate net worth and means of providing for its current financial needs and possible personal contingencies;

    (e)
    the Purchaser is not acquiring the Shares as a result of any form of general solicitation or general advertising including advertisements, articles, notices or other communications published in any newspaper, magazine or similar media or broadcast over radio, or television, or any seminar or meeting whose attendees have been invited by general solicitation or general advertising;

    (f)
    the Purchaser acknowledges that the purchase and sale of the Shares may lead to adverse tax consequences and the Purchaser acknowledges and confirms that the Purchaser has been advised to seek, and has sought or has otherwise elected not to obtain tax advice; and

    3.
    Independent Legal Advice

    3.1
    The Purchaser acknowledges that:

    (a)
    the Purchaser has been requested to obtain its own independent legal advice;

    (b)
    the Purchaser has been given adequate time to obtain independent legal advice;

    (c)
    by signing this Agreement, the Purchaser confirms that it fully understands this Agreement; and
     (d) by signing this Agreement without first obtaining independent legal advice, the Purchaser waives its right to obtain legal advice.

    4.
    Legending and Registration of the Shares

    4.1
    The Purchaser hereby acknowledges that a legend may be placed on the certificates representing the Shares to the effect that the Shares represented by such certificates are subject to a hold period and may not be traded until the expiry of such hold period except as permitted by applicable securities legislation. The Purchaser hereby acknowledges and agrees to the Company making a notation on its records or giving instructions to the registrar and transfer agent of the Company in order to implement the restrictions on transfer set forth and described in this Agreement.

    5.
    Further Assurances

    5.1
    The parties to this Agreement hereby agree to execute and deliver all such further documents and instruments and do all acts and things as may be necessary or convenient to carry out the full intent and meaning of and to effect the transactions contemplated by this Agreement.

    6.
    Entire Agreement

    6.1
    This Agreement contains the entire agreement between the parties with respect to the subject matter hereof and supersede all prior arrangements and understandings, both written and oral, expressed or implied, with respect thereto. Any preceding correspondence or offers are expressly superseded and terminated by this Agreement.

    7.
    Electronic Means

    7.1
    Delivery of an executed copy of this Agreement by electronic facsimile transmission or other means of electronic communication capable of producing a printed copy will be deemed to be execution and delivery of this Agreement as of the date set forth on page one of this Agreement.

    8.
    Counterparts

    8.1
    This Agreement may be executed in any number of counterparts, each of which, when so executed and delivered, shall constitute an original and all of which together shall constitute one instrument.

    9.
    Jurisdiction

    9.1
    This Agreement shall be exclusively construed and enforced in accordance with the laws of the Province of British Columbia.

    10.
    Currency

    10.1
    All funds referenced in this Agreement are stated in United States dollars.

    IN WITNESS WHEREOF the parties hereto have duly executed this Agreement as of the date first written above.


                                                                                             /s/ Katie Field
                                                                                             Halo Collective Inc.

                                                                                         /s/
    1173727 BC LTD.
    Get the next $AKAN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AKAN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AKAN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Univest Securities, LLC Announces Closing of $5 Million Underwritten Public Offering for its Client Akanda Corp. (NASDAQ: AKAN)

      New York, March 27, 2024 (GLOBE NEWSWIRE) -- Univest Securities, LLC ("Univest"), a member of FINRA and SIPC, and a full-service investment bank and securities broker-dealer firm based in New York, today announced the closing of underwritten public offering (the "Offering") of 3,087,443 common stock priced at $0.1217 per share, with pre-funded warrants exercisable for 37,997,190 shares with respect to the underwritten public offering for its client Akanda Corp. (NASDAQ:AKAN) ("Akanda" or the "Company"), an international medical cannabis company. Under the terms of the securities purchase agreement, the Company has agreed to sell to the institutional investors a total of 3,087,443 sh

      3/27/24 4:45:00 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Akanda Corp. Announces Signing of Option to Develop Canadian THC and CBD Farming Facility

      International medical cannabis company Akanda Corp. ("Akanda" or the "Company") (NASDAQ:AKAN, WKN: A3DG83))) announces that Akanda (the "Optionee" the "Company") and 1107385 B.C. LTD (the "Owner") have agreed upon terms to purchase farming land and related operations and licenses. The key deal terms are as follows: Akanda will issue a non-refundable payment equal to One Million Eight Hundred Thousand United States Dollars (USD1,800,000) and if paid in common shares of Akanda will be based on formula to calculate the per share price as set forth in the agreement. The initial payment will be broken up into the First Option Payment, the Second Option Payment and the Third Option Payment, u

      9/20/23 9:00:00 AM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Akanda Corp. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

      International medical cannabis platform company Akanda Corp. ("Akanda" or the "Company") (NASDAQ:AKAN) today announced that the Company has received a written notification (the "Notification Letter") on July 3, 2023 from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). It resulted from the fact that the closing bid price of the Company's common shares, no par value ("Common Shares"), was below $1.00 per share for a period of 30 consecutive business days. The Notification Letter does not impact the Company's listing on the

      7/6/23 4:18:00 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $AKAN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Akanda Corp. (Amendment)

      SC 13D/A - AKANDA CORP. (0001888014) (Subject)

      2/20/24 6:01:03 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Akanda Corp.

      SC 13D - AKANDA CORP. (0001888014) (Subject)

      2/20/24 5:17:13 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Akanda Corp. (Amendment)

      SC 13G/A - AKANDA CORP. (0001888014) (Subject)

      2/20/24 12:55:32 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $AKAN
    Leadership Updates

    Live Leadership Updates

    See more
    • Halo Collective Announces Change of Auditors and Failure to File Cease Trade Order

      Toronto, Ontario--(Newsfile Corp. - June 22, 2023) - Halo Collective Inc. (NEO: HALO) (OTCQB:HCANF) (FSE: A9K0) ("Halo" or the "Company") announces today that it has changed its auditor (the "Change of Auditor") from Macias Gini & O'Connell LLP (the "Former Auditor") to GreenGrowth CPAs (the "Successor Auditor"). The Former Auditor resigned effective June 19, 2023, and the Company's board of directors, upon the audit committee's recommendation, appointed the Successor Auditor to fill the resulting vacancy until the close of the next annual meeting of the Company's shareholders.There was no modified opinion, or other opinion, issued by the Former Auditor in connection with its audit of the Co

      6/22/23 1:06:00 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Canmart Ends CEO Service Agreement; Akanda Approves Appointment of Director

      International medical cannabis platform company Akanda Corp. ("Akanda" or the "Company") (NASDAQ:AKAN) today announced its subsidiary Canmart Ltd. brought Tejinder Virk's Service Agreement dated June 2, 2021 (the "Service Agreement") to an immediate end with effect from February 13th, 2023. As disclosed on February 7th, 2023, the Company disclosed Mr. Virk's attempt to end the Service Agreement without providing the requisite period of notice required under the Service Agreement, his interpretation of the Service Agreement, and allegations of Breach of Contract. On February 13th, 2023, the Company informed Mr. Virk that it had reached the conclusion that it has a right to bring the Service

      2/16/23 5:05:00 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • /R E P E A T -- Halo Collective Appoints Katie Field as Chairman of the Board/

      TORONTO, Aug. 12, 2022 /PRNewswire/ -  Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced the appointment of Katie Field, Chief Executive Officer of Halo, to Chairman of the board of directors of the Company (the "Board"), effective immediately. Current Chairman Ryan Kunkel has resigned from the Board to focus on other professional endeavors. To the knowledge of the Company, Ms. Field is the second woman to serve as Chairman and CEO of a publicly traded cannabis company, the first being Kim Rivers of Trulieve (CSE:TRUL). Ca

      8/12/22 8:00:00 AM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $AKAN
    Financials

    Live finance-specific insights

    See more
    • Halo Collective Completes Acquisition of Premium Indoor Grow and Distribution Hub in Portland, Oregon

      TORONTO, Sept. 22, 2022 /PRNewswire/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced, further to its press release dated August 27, 2021, that it has completed the acquisition of all of the substantial assets of three operating entities doing business as Pistil Point in Oregon which collectively hold multiple cannabis licenses. With this transaction, Halo now has full ownership of a range of indoor and outdoor cultivation, manufacturing, and distributions assets, along with an expanded library of genetics that is expected to allow the Company to continue to execute its vertically integrated strategy in Oregon with enhanced compet

      9/22/22 5:00:00 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • Halo Collective Announces Westwood Dispensary Completion, Local Inspections Passed, and Planned Opening for Second Budega™ in California

      TORONTO, April 12, 2022 /PRNewswire/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQX:HCANF) (Germany: A9KN) today announced that its Budega Westwood Dispensary passed its Los Angeles inspection and is expected to open within 30 days. The Budega Westwood location is perfectly located nestled in between Westwood to the west and Beverly Hills to the east, right off of one of LA's most traveled and famous thoroughfares for locals and visitors, the Santa Monica Boulevard (10461 Santa Monica Blvd) and within two miles of the University of Los Angeles California campus. The facility is leased and near complete with renovations of its approximately 1,500 square foot prime retail

      4/12/22 4:40:00 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care

    $AKAN
    SEC Filings

    See more
    • SEC Form 6-K filed by Akanda Corp.

      6-K - AKANDA CORP. (0001888014) (Filer)

      5/1/25 5:00:02 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 20-F filed by Akanda Corp.

      20-F - AKANDA CORP. (0001888014) (Filer)

      4/30/25 3:00:22 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 6-K filed by Akanda Corp.

      6-K - AKANDA CORP. (0001888014) (Filer)

      4/18/25 1:46:03 PM ET
      $AKAN
      Medicinal Chemicals and Botanical Products
      Health Care